Martin Gary J, Teklu Meron, Mandieka Edwin, Feinglass Joe
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Cardiol Res Pract. 2022 Apr 27;2022:7537510. doi: 10.1155/2022/7537510. eCollection 2022.
We sought to characterize the level of LDL-C control and identify opportunities for improvement and characteristics of patients who were undertreated.
Study patients were from a large multihospital system, age <90, with documentation of at least two encounters with a CAD diagnosis or procedure before a first measured LDL-C level and a last recorded LDL-C measurement over a minimum six-month (median = 22 months, IQR = 15-26 months) follow-up from January 2017 to September 2019. Linear regression analysis for last recorded LDL-C level was used to analyze the effects of statin intensity and patient characteristics.
Among 15,111 eligible patients, mean age was 68.4 (SD = 10.8), 68.7% were male, and 79.4% were non-Hispanic White. At follow-up, 87.8% of patients were prescribed a statin, 9.7% were on ezetimibe, and 0.5% were on a PCSK9 inhibitor. Mean LDL-C at follow-up was 75.6 mg/dL and 45.5% of patients were on high-intensity treatment. Higher LDL-C values were associated with female sex, younger patients, non-Hispanic Black patients, high poverty or out of state zip code, Medicaid, or angina as the qualifying diagnosis. For 332 clinicians with >10 patients in the cohort, mean last recorded LDL-C values ranged from 47 to 102 mg/dL.
There were important variations in LDL-C control between patients in our health system with the same indication for treatment. Variation in treatment among physicians is an area ripe for quality improvement interventions. This study may be easily reproduced by other medical centers and used for highlighting both patient and physician opportunities for improvement.
我们试图描述低密度脂蛋白胆固醇(LDL-C)的控制水平,确定改善的机会以及治疗不足患者的特征。
研究患者来自一个大型多医院系统,年龄<90岁,在2017年1月至2019年9月至少六个月(中位数=22个月,四分位间距=15 - 26个月)的随访中,有至少两次冠心病诊断或治疗记录,且有首次测量的LDL-C水平和最后记录的LDL-C测量值。对最后记录的LDL-C水平进行线性回归分析,以分析他汀类药物强度和患者特征的影响。
在15111名符合条件的患者中,平均年龄为68.4岁(标准差=10.8),68.7%为男性,79.4%为非西班牙裔白人。随访时,87.8%的患者服用他汀类药物,9.7%服用依折麦布,0.5%服用前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂。随访时的平均LDL-C为75.6mg/dL,45.5%的患者接受高强度治疗。较高的LDL-C值与女性、年轻患者、非西班牙裔黑人患者、高贫困率或州外邮政编码、医疗补助或心绞痛作为合格诊断相关。对于队列中拥有超过10名患者的332名临床医生,最后记录的LDL-C平均水平在47至102mg/dL之间。
在我们医疗系统中具有相同治疗指征的患者之间,LDL-C控制存在重要差异。医生之间的治疗差异是质量改进干预的一个成熟领域。本研究可被其他医疗中心轻松复制,并用于突出患者和医生的改进机会。